Neurosense Therapeutics Ltd (OQ:NRSN)
Business Focus: Bio Therapeutic Drugs
May 02, 2024 09:19 am ET
NeuroSense Announces First Quarter 2024 Business Update
CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
Apr 22, 2024 08:30 am ET
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
CAMBRIDGE, Mass., April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer's Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense's currently ongoing Phase 2 AD clinical trial, leverages Genetika+'s state-of-the-art technology that derives frontal cortex neurons from individual patients' blood to quantify drug-induced neur
Apr 18, 2024 08:30 am ET
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consistent trend toward impact on Neurofilament biomarker levels
Apr 12, 2024 08:30 am ET
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes
Apr 10, 2024 07:00 pm ET
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
CAMBRIDGE, Mass., April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care focused institutional investor for the purchase and sale of 2,980,000 ordinary shares (or ordinary share equivalents in lieu thereof) in a registered direct offering and ordinary warrants to purchase up to 2,980,000 ordinary shares in a concurrent private placement (together with the registered direc
Apr 09, 2024 08:30 am ET
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration fieldLonza to develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes ("NDEs"), set to be integrated into the clinical development program of PrimeC by NeuroSenseLonza's Dev-on-Demand solution to enable NeuroSense to access Lonza's process development with rapid initiation, execution, and delivery of workBASEL, Switzerland and CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ -- Lonza (SIX: LONN), a global development and manufacturing part
Apr 05, 2024 09:29 am ET
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
CAMBRIDGE, Mass., April 5, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today reported its financial results for the year ended December 31, 2023 and provides a business update.
Feb 21, 2024 07:30 am ET
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALSStandard ALS Measure ALSFRS-R already demonstrated a statistically significant effect of PrimeC on slowing down disease progressionFurther analysis of PARADIGM is on track with neurofilament results expected in Q1 and TDP-43 and ProstaglandinJ2 biomarkers expected in the first half of 2024CAMBRIDGE, Mass., Feb. 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, toda
Feb 07, 2024 08:27 am ET
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
CAMBRIDGE, Mass., Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing.
Jan 30, 2024 08:30 am ET
NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
HERZLIYA, ISRAEL / ACCESSWIRE / January 30, 2024 / Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and ultimately death within two to five years from diagnosis. Each year, about 5,000 people in the U.S. are diagnosed with this devastating disease, amounting to 15 new cases daily, according to the ALS Association.
Jan 09, 2024 07:45 am ET
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussions
Dec 27, 2023 04:00 pm ET
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
This notification has no immediate effect on the listing or trading of NeuroSense's ordinary shares on the Nasdaq Capital MarketCAMBRIDGE, Mass., Dec. 27, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received a notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it no longer satisfied the minimum $2.5 million stockholders' equity requirement for continued listing on Nasda
Dec 14, 2023 08:24 am ET
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol (PP) population analysisNeurofilament biomarker results from Biogen collaboration expected in January 2024Primary biomarker endpoints, TDP-43 and Prostagladin2, are expected in H1 2024PrimeC's meaningful effect magnitude, strong safety profile, and unique mechanism of action will be discussed with the FDA and other regulatory agencies in an End of Phase 2 meeting in H1 2024CAMBRIDGE, Mass., Dec. 14, 2023 /PR
Dec 05, 2023 08:31 am ET
Thinking about buying stock in Macy's Inc, Altamira Therapeutics, Neurosense Therapeutics, Cytosorbents, or Designer Brands?
NEW YORK, Dec. 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for M, CYTO, NRSN, CTSO, and DBI.
Dec 05, 2023 07:00 am ET
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense's lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a safety and tolerability profile comparable to placeboMeaningful slowing of disease progression: 29% difference (P=0.12) in favor of ALSFRS-R outcome for patients treated with PrimeC vs placeboSlow Vital Capacity: observed a positive trend in favor of patients treated with PrimeC compared to placeboNeurofilament biomarker results from Biogen collaboration expected in January 2024Primary biomarker end
Dec 04, 2023 03:01 pm ET
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
Data to be announced in a premarket press release followed by a conference call at 8:30 am ET
Nov 28, 2023 07:45 am ET
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early December 2023Patients who completed the 18-month PARADIGM trial, including the 6-month double-blind study plus the 12-month open label extension, have requested to continue treatment with PrimeC First patient in Phase 2 Alzheimer's disease study expected to be enrolled December 2023Cash runway beyond topline clinical study readouts, into Q2 2024CAMBRIDGE, Mass., Nov. 28, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company develo
Nov 13, 2023 08:20 am ET
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has concluded a successful Type D meeting with the U.S. Food and Drug Administration (FDA) for PrimeC in the treatment of amyotrophic lateral sclerosis (ALS). FDA Type D meetings are focused on a narrow set of issues at key decision points to provide timely feedback critical to move a drug development
Nov 09, 2023 08:00 am ET
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
- Last patient completed the double-blind segment of PARADIGM, a Phase 2b ALS Trial
Nov 06, 2023 07:30 am ET
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
Clinical efficacy results (secondary endpoints) and safety results (primary endpoints) expected December 2023Biogen collaboration biomarker results expected Q1 2024Primary biomarker endpoints to be reported H1 2024 CAMBRIDGE, Mass., Nov. 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has completed dosing of the last patient in the double-blind segment of its Phase 2b amyotrophic lateral sclerosis (ALS) trial of PrimeC (PARADIGM). PrimeC is designed to synergistically
Nov 01, 2023 09:00 am ET
NeuroSense Therapeutics to Participate in BIO-Europe Fall
CAMBRIDGE, Mass., Nov. 1, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Chief Medical Officer Dr. Ferenc Tracik will participate in the 29th annual BIO-Europe Fall partnering conference on November 6-8, 2023 in Munich, Germany.
Oct 19, 2023 10:30 am ET
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC
HERZLIYA, ISRAEL / ACCESSWIRE / October 19, 2023 / Induced pluripotent stem cells (iPSCs) have emerged as a promising tool in the field of research and therapy for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). ALS is a progressive disorder that affects motor neurons, leading to muscle weakness, paralysis and ultimately death. iPSCs are adult cells that have been reprogrammed to behave like embryonic stem cells, capable of differentiating into various cell types. By generating iPSCs from people living with ALS, researchers are able to study disease-spe
Oct 17, 2023 08:30 am ET
NeuroSense CEO Provides Q3 2023 Update
Phase 2b ALS topline results expected December 2023
Oct 04, 2023 09:10 am ET
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
In collaboration with the University of Southern California's Ichida Stem Cell Lab, PrimeC was shown to significantly increase survival rate of induced motor neurons in an in vitro study utilizing induced pluripotent stem cells (iPSCs) generated from people living with ALSResults reinforce previous findings in multiple models In a previous independent study carried out by Dr. Ichida, PrimeC performed among the best in improving motor neuron survival when compared to several other ALS drugs in development and two ALS FDA approved drugs CAMBRIDGE, Mass., Oct. 4, 2023 /PRNewswire/ -- NeuroSense
Oct 03, 2023 07:00 am ET
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now
EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emerging Growth Conference on October 4th and 5th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors,...
Sep 20, 2023 09:05 am ET
European Medicines Agency Grants NeuroSense SME Status
SME status offers regulatory guidance and engagement in dialogue with EMANeuroSense to open an EU office in Ulm, GermanyCompany plans to enroll patients at multiple sites across Europe in its planned Phase 3 pivotal ALS study of PrimeCCAMBRIDGE, Mass., Sept. 20, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that it has opened an EU Office as well as been granted the Small and Medium-Sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers signifi
Sep 19, 2023 09:00 am ET
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
Patents valid through 2038Clinical topline results from Phase 2b ALS trial expected in H2 2023CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that the European, Japan, and Israel Patent Offices have granted the Company a key patent relating to "Compositions comprising an anti-inflammatory drug and a dicer activator for use in treatment of neuronal diseases." The patents relate to NeuroSense's unique fixed-dose combination of ciprofloxacin and cel
Sep 14, 2023 09:00 am ET
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.
Company to deliver poster presentation regarding its PARADIGM Phase 2b ALS study at NEALS
Jul 17, 2023 08:30 am ET
NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023
Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts may register for the invitation-only event.
Jul 11, 2023 09:00 am ET
NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit
CAMBRIDGE, Mass., July 11, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it will participate in two upcoming conferences that aim to advance treatments and solutions to improve the lives of people living with amyotrophic lateral sclerosis (ALS).
Jul 06, 2023 08:30 am ET
NeuroSense CEO Provides Q2 2023 Update
View video here: Link
Jun 22, 2023 08:30 am ET
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
CAMBRIDGE, Mass., June 22, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care focused institutional investor for the purchase and sale of 3,000,000 ordinary shares (or ordinary share equivalents in lieu thereof) in a registered direct offering and ordinary warrants to purchase up to 3,000,000 ordinary shares in a concurrent private placement (together with the registered direct offering, the "offerin
Jun 01, 2023 08:45 am ET
NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
CAMBRIDGE, Mass., June 1, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced financial results for the quarter ended March 31, 2023 and provided a business update.
May 15, 2023 09:05 am ET
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
96% of participants who completed the trial opted to receive treatment with PrimeC in a 12-month open label extensionTopline results expected Q4 2023CAMBRIDGE, Mass., May 15, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the completion of enrollment in PARADIGM, a multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial of PrimeC in people living with amyotrophic lateral sclerosis (ALS). Study participants are dosed for 6 months after being rand
May 02, 2023 08:30 am ET
NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study
Statistically significant decreased levels of novel biomarker AGO2 (p= 0.002) observed in newly diagnosed people living with Parkinson's disease (PD) compared to healthy individualsNeuroSense's combination platform has been observed in a clinical trial to induce an increase of AGO2 in ALS patients, indicating therapeutic potential in PDNeuroSense is exploring co-development of PD asset with potential collaboratorsCAMBRIDGE, Mass., May 2, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, toda
Apr 17, 2023 09:05 am ET
NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
CAMBRIDGE, Mass., April 17, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the Company's clinical and operational developments during the first quarter of 2023.
Mar 27, 2023 09:15 am ET
NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
In vitro studies to test the effects of PrimeC on key pathways involved in ALS including TDP-43 accumulation, autophagy defects, mitochondrial dysfunction, and oxidative stressPreliminary results from this collaboration will be presented by Dr. Zimri at the upcoming AD/PD 2023 Advances in Science & Therapy Conference PrimeC is currently being evaluated in PARADIGM, a Phase 2b ALS trialCAMBRIDGE, Mass., March 27, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has sig
Mar 23, 2023 09:05 am ET
NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
Biomarkers show potential efficacyPrimeC is currently being evaluated for the treatment of ALS in a Phase 2b study with topline results expected in H2 2023Phase 2 double-blind proof-of-concept AD study is expected to commence in H1 2023CAMBRIDGE, Mass., March 23, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Vice President of R&D, Dr. Shiran Zimri, will deliver two presentations at the AD/PD™ 2023 Advances in Science & Therapy Conference which takes place Ma
Mar 22, 2023 08:45 am ET
NeuroSense Announces Year End 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass., March 22, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2022, as filed with the Securities and Exchange Commission, is available through its website (https://www.neurosense-tx.com), and provided a business update.
Mar 16, 2023 08:30 am ET
NeuroSense Therapeutics to Participate in BIO-Europe Spring
CAMBRIDGE, Mass., March 16, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Chief Medical Officer Dr. Ferenc Tracik and VP of Business Development Nedira Salzman-Frenkel will participate in the 17th annual BIO-Europe Spring partnering conference on March 20-22, 2023 in Basel, Switzerland.
Mar 14, 2023 08:40 am ET
NEUROSENSE THERAPEUTICS LTD. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023
CAMBRIDGE, Mass., March 14, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, March 21, 2023, at 11:00 AM PST and Tuesday, March 28, 2023 at 10:00 AM EST. NeuroSense Therapeutics Ltd. welcomes stakeholders, investors, and other individual followers to register and attend these live events.
Feb 13, 2023 07:30 am ET
NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts
View video here: LINK
Feb 09, 2023 08:20 am ET
NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
QuantalX's direct electrophysiology imaging technology (Delphi-MD) expected to provide multiple clinically objective and accurate measurements in NeuroSense's Phase 2 double-blind proof-of-concept clinical study in Alzheimer's disease, expected to commence in H1 2023
Feb 08, 2023 08:14 am ET
NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
PARADIGM protocol is approved in four countries: Israel, Italy, Canada, and GermanyTopline results expected in H2 2023CAMBRIDGE, Mass., Feb. 8, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that Germany's Federal Institute for Drugs and Medical Devices (BfArM) approved the Company's Clinical Trial Application (CTA) to enroll patients in PARADIGM, its Phase 2b study of its lead combination drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS).
Feb 06, 2023 08:12 am ET
NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study
Receives regulatory approval from Health Canada to commence enrollment PARADIGM topline read-out expected H2 2023CAMBRIDGE, Mass., Feb. 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that Health Canada approved the commencement of patient enrollment in Canada for the Company's Phase 2b PARADIGM study of its combination therapy PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). Currently, over 50% of patients have been enrolled in PARADIGM with topline resu
Jan 19, 2023 09:57 am ET
Thinking about buying stock in Neurosense Therapeutics, American Airlines, General Electric, Pfizer, or Ardelyx?
NEW YORK, Jan. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NRSN, AAL, GE, PFE, and ARDX.
Jan 19, 2023 07:52 am ET
NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study
Elevated levels of novel biomarker TDP-43 in Alzheimer's disease (AD) show the therapeutic potential of NeuroSense's combination platformPhase 2 double-blind proof-of-concept clinical study expected to commence in H1 2023CAMBRIDGE, Mass., Jan. 19, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced final results from a biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Alzheimer's disease (AD). Preliminary resul
Dec 01, 2022 08:05 am ET
NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass., Dec. 1, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2022 and provided a business update.
Nov 16, 2022 08:34 am ET
NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS
CAMBRIDGE, Mass., Nov. 16, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian Medicines Agency (AIFA) to commence patient enrollment in Italy for PARADIGM, the Company's Phase 2b clinical trial of its lead drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS). PARADIGM is currently enrolling patients in Israel and recently received clearance from the U.S. Food and Drug Administration to open clinical sites for p
Nov 15, 2022 07:30 am ET
NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study
NeuroSense Therapeutics receives FDA clearance to commence patient enrollment in the U.S. with PrimeC, a novel combination therapyFollows a successful U.S. pharmacokinetic (PK) study which confirmed PrimeC's favorable extended release propertiesCAMBRIDGE, Mass., Nov. 15, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) to enroll patients in the U.S. for its Phase 2b PARADIGM
Oct 27, 2022 08:50 am ET
NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences
CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming conferences.
Oct 21, 2022 09:25 am ET
NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany
CAMBRIDGE, Mass, Oct. 21, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in the BIO-Europe® Partnering Conference on October 24-26, 2022 in Lepzing, Germany.
Oct 18, 2022 08:30 am ET
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video
View the Nasdaq Opening Bell Ringing & CEO Message Here: LINK
Oct 12, 2022 08:30 am ET
NeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on October 13, 2022 in New York City
Investors and analysts interested in participating in the Summit via webinar may register here: LINK
Sep 29, 2022 08:30 am ET
NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference
Company's lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023
Sep 28, 2022 08:30 am ET
NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US
Pharmacokineticic (PK) profile of PrimeC supports the formulation's extended release properties, as the active components are released simultaneously
Sep 21, 2022 08:51 am ET
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
Biomarker data to be presented provide indication of PrimeC's efficacy in ALSPhase IIb PARADIGM ALS trial's primary endpoints include biomarkers and ALS-related hallmarksTopline results expected H1 2023CAMBRIDGE, Mass., Sept. 21, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced scientific presentations at two upcoming conferences.
Sep 20, 2022 08:45 am ET
NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial
PrimeC is safe and tolerable at over 4x the maximal clinical dose Data support current Phase IIb PARADIGM study design, new PrimeC formulation, and potential favorable clinical trial outcomeCAMBRIDGE, Mass., Sept. 20, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced positive results from its Good Laboratory Practices (GLP) toxicology study designed to evaluate the toxicological profile and toxicokinetics of the combination of celecoxib and ciprofloxacin, the components of Pr
Sep 19, 2022 09:14 am ET
NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Groundbreaking ALS biomarker research: Marks the first publication of NeuroSense's novel biomarker results demonstrating PrimeC's effect on ALS related hallmarksPrimeC showed a statistically significant impact on key disease-related biomarkers including TDP-43, which increases with disease progression, and LC3, a key autophagy marker Based on successful Phase IIa results, NeuroSense commenced PARADIGM, a Phase IIb clinical trial in May 2022CAMBRIDGE, Mass., Sept. 19, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe
Aug 31, 2022 09:00 am ET
NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass., Aug. 31, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June 30, 2022 and provided a business update.
Aug 02, 2022 08:30 am ET
NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study
- NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments
Jul 28, 2022 09:00 am ET
NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML
NeuraLight's platform technology uses computer vision, artificial intelligence (AI), deep learning algorithms, and machine learning (ML) to identify and track oculometric digital biomarkers to transform clinical development, diagnostics, and precision medicine in neurologyThe NeuroSense-NeuraLight collaboration entails sharing and tracking patient data to advance the identification and use of ALS digital biomarkersCAMBRIDGE, Mass., AUSTIN, TX, and TEL AVIV, Israel, July 28, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for se
Jul 18, 2022 08:30 am ET
NeuroSense Therapeutics CEO Provides Key Corporate Update Video
View video here: https://youtu.be/KCT2wzOqmNo
Jun 30, 2022 08:30 am ET
NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study
Biomarkers show the potential of NeuroSense's combination drug CogniC to treat Alzheimer's diseaseCogniC is expected to advance into clinical trials in 2023CAMBRIDGE, Mass., June 30, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense's combination drug for the treatment of Alzheimer's disease (AD).
Jun 27, 2022 09:31 am ET
Thinking about buying stock in Neurosense Therapeutics, Boxed, Snap, RealReal, or Accelerate Diagnostics?
NEW YORK, June 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NRSN, BOXD, SNAP, REAL, and AXDX.
Jun 27, 2022 08:30 am ET
NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study
Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline in these biomarkers in patients treated in NeuroSense's Phase IIa study with PrimeCNew biomarker data in people with ALS validates NeuroSense's clinical strategyCAMBRIDGE, Mass., June 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced results from Stage III of its biomarker study
Jun 22, 2022 08:30 am ET
NeuroSense CEO to be Panelist at Maxim Group's Innovations in ALS: Exploring New Treatments In Development on June 28, 2022
CAMBRIDGE, Mass, June 22, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the Company will participate in Maxim Group's panel discussion on Innovations in ALS: Exploring New Treatments In Development, which will take place on Tuesday, June 28th, 2022.
Jun 01, 2022 08:30 am ET
NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC
Phase IIa study successfully met safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biomarkers PrimeC has Orphan Drug Designation with the FDA and EMACAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has enrolled the first patient in its Phase IIb PARADIGM trial for its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). PAR
May 31, 2022 08:30 am ET
NeuroSense Announces First Quarter 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass., May 31, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2022 and provided a business update.
May 23, 2022 08:30 am ET
NeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022
Ferenc Tracik, MD to deliver presentation - "From Monotherapy to Combination Therapy: Considering a Paradigm Shift to Target Complexity of ALS"Phase IIb ALS study for NeuroSense's combination therapy PrimeC expected to commence Q2 2022CAMBRIDGE, Mass., May 23, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Chief Medical Officer, Dr. Ferenc Tracik, will deliver a presentation on May 26th at the ALS Drug Development Summit, which is scheduled to take place on May 24 – 26
Apr 11, 2022 08:30 am ET
NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS
Study conducted under FDA cleared protocol in parallel with international Phase IIb trial expected to commence in Q2 2022
Apr 06, 2022 08:30 am ET
NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC
- Patent valid through 2038
Mar 30, 2022 08:15 am ET
NeuroSense Therapeutics CEO Provides Key Corporate Update Video
CAMBRIDGE, Mass., March 30, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today released a video presentation with a corporate update from its Founder and CEO Alon Ben-Noon, View video here: https://youtu.be/MMXhD9DhPZg
Mar 25, 2022 08:00 am ET
NeuroSense Therapeutics Receives $4 Million Through Warrant Exercises
- Warrants exercised at $6 per share
Mar 21, 2022 08:30 am ET
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
CAMBRIDGE, Mass., March 21, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pharmacokinetic study of PrimeC in healthy adult subjects. PrimeC is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of amyotrophic lateral sclero
Mar 15, 2022 09:00 am ET
NeuroSense Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT
CAMBRIDGE, Mass., March 15, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that the company's CEO, Alon Ben-Noon, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.
Mar 01, 2022 08:00 am ET
NeuroSense Therapeutics Granted Key Patent for its ALS Drug PrimeC in Australia
CAMBRIDGE, Mass., March 1, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the grant of a key patent in Australia. The patent, which was already granted in the US in 2021 (US 10,980,780), is titled "Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases", and covers the Company's unique fixed-dose combination of ciprofloxacin and celecoxib, two US FDA-approved drugs that are the active ingredients in PrimeC, NeuroSense's le
Feb 24, 2022 08:15 am ET
NeuroSense Therapeutics to Present at American Society for Experimental Neurotherapeutics Annual Meeting on March 3rd
CAMBRIDGE, Mass., Feb. 24, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that Dr. Shiran Zimri, the Company's Head of Scientific Programs, will deliver a presentation titled "Breaking the Paradigm – PrimeC as a Novel Approach to ALS Therapy" at the American Society for Experimental Neurotherapeutics (ASENT) 2022 Annual Meeting on Thursday, March 3, 2022. NeuroSense, together with Amylyx Pharmaceuticals, and the National Institute of Neuroscience in Tokyo, will co-lead a s
Feb 22, 2022 07:30 am ET
NeuroSense Therapeutics to Present at Aegis Virtual Conference
CAMBRIDGE, Mass., Feb. 22, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 25th at 8:30AM Eastern. The conference will span three days, starting on February 23rd until February 25th from 8:30AM until 5PM EST.
Jan 31, 2022 08:00 am ET
NeuroSense Therapeutics to Present at BIO CEO & Investor Conference
CAMBRIDGE, Mass., Jan. 31, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that Alon Ben-Noon, NeuroSenses's CEO will present a company overview at the BIO CEO & Investor Conference on February 15th at 9:30AM Eastern. The conference will span four days, starting from February 14th until February 17th at the Marriott Marquis in New York City.
Jan 27, 2022 07:30 am ET
NeuroSense Therapeutics Extends ALS Biomarker Collaboration with Massachusetts General Hospital
CAMBRIDGE, Mass., Jan. 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for neurodegenerative diseases, announced today the initiation of the third stage of a collaborative biomarker study with Massachusetts General Hospital (MGH). The extension of this collaborative effort follows two prior successful studies conducted with the novel neuron derived exosomes platform, also completed in collaboration with MGH.
Jan 04, 2022 08:23 am ET
NeuroSense Therapeutics, Ltd. Announces the Presentation of Phase IIa Study Results at Four International Conferences
CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that presentation of the company's Phase IIa clinical trial results have been accepted at the 16th International Conference on Alzheimer's & Parkinson's (AD/PD) to be held in Barcelona in March 2022. AD/PD is an international medical and scientific conference for Alzheimer's & Parkinson's disease and other neurological diseases.
Dec 21, 2021 08:00 am ET
NeuroSense Therapeutics Ltd. Expands Board of Directors and Adds Chief Medical Officer to Leadership Team
CAMBRIDGE, Mass., Dec. 21, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the expansion of its board of directors with the appointment of four new directors upon the closing of the company's recent IPO. The new directors will join the current directors, Mark Leuchtenberger, Chairman of the Board, and Alon Ben-Noon, the CEO and founder.
Dec 13, 2021 03:01 pm ET
NeuroSense Therapeutics Announces Closing of Initial Public Offering on Nasdaq Capital Market
CAMBRIDGE, Mass., Dec. 13, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd., (Nasdaq: NRSN) ("NeuroSense"), a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as ALS, Alzheimer's and Parkinson's disease, today announced the closing of its previously announced initial public offering on the Nasdaq Capital Market of 2,000,000 units, each consisting of one ordinary share and a warrant representing the right to purchase one ordinary share with an exercise price of $6.00 per share, at a
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.